Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

Anaptys Bio (NASDAQ:ANAB) stock plunged 33% Wednesday after the company said it was scrapping further development of its drug ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...